Omnicell, Inc. (NASDAQ:OMCL) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Omnicell, with seven buy ratings and two holds among nine firms. The average 12-month price target is $57.86, although several analysts recently lowered their targets.
• Institutional investors own 97.7% of Omnicell’s stock; notable activity included BlackRock initiating a roughly $313 million position and California’s state teachers’ retirement system substantially increasing its stake.
• Omnicell’s latest quarter exceeded expectations, with EPS of $0.94 versus a $0.47 consensus estimate and revenue of $312.2 million, up 7.4% year over year. Shares opened at $33.51, near the lower end of their 52-week range.

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $57.8571.

A number of analysts have issued reports on OMCL shares. Wells Fargo & Company reduced their price target on shares of Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Weiss Ratings raised shares of Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 18th. Piper Sandler restated an "overweight" rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. KeyCorp reaffirmed an "overweight" rating on shares of Omnicell in a report on Monday, August 24th. Finally, Zacks Research upgraded Omnicell from a "strong sell" rating to a "hold" rating in a research report on Monday, September 7th.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently bought and sold shares of OMCL. BlackRock Inc. purchased a new stake in Omnicell in the 2nd quarter worth about $313,044,000. Dimensional Fund Advisors LP grew its stake in Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company's stock worth $81,791,000 after acquiring an additional 137,834 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Omnicell by 4,074.3% during the second quarter. California State Teachers Retirement System now owns 2,100,621 shares of the company's stock valued at $87,218,000 after acquiring an additional 2,050,298 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company's stock valued at $47,095,000 after acquiring an additional 27,497 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Omnicell by 31.3% in the first quarter. Bank of America Corp DE now owns 580,875 shares of the company's stock valued at $19,390,000 after purchasing an additional 138,537 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Trading Up 2.2%

OMCL stock opened at $33.51 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. Omnicell has a 1-year low of $29.06 and a 1-year high of $55.00. The business has a 50 day simple moving average of $38.24 and a two-hundred day simple moving average of $39.02. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of 39.89, a PEG ratio of 0.82 and a beta of 0.97.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million for the quarter, compared to analysts' expectations of $310.21 million. During the same quarter last year, the business posted $0.45 earnings per share. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts anticipate that Omnicell will post 1.41 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.